Cagri-Reta refers to the combination of Cagrilintide (a long-acting amylin analogue) and Retatrutide (triple GLP-1/GIP/GcgR agonist). Cagrilintide acts on amylin receptors in the hypothalamus to reduce appetite via a complementary and additive mechanism to GLP-1 agonism. Clinical data from the REDEFINE trials has shown this combination achieving the highest weight reduction results in any published obesity pharmacotherapy study. Supplied as a research vial for preclinical investigation.
Add 2 mL bacteriostatic water for 5,000 mcg/mL.
Use our peptide reconstitution calculator →
Store lyophilised at −20 °C. Reconstituted: 4 °C, use within 14 days.
Every NewChem batch of Cagri-Reta is independently tested prior to dispatch. Your COA documents HPLC purity (≥99%), identity confirmation via mass spectrometry, endotoxin screening, and a unique batch ID for full traceability. Sample COAs are available on request before purchase.
For a detailed step-by-step reconstitution guide for Cagri-Reta, including BAC water measurements, syringe unit conversions, and storage protocols, see our dedicated guide:
